Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 227

The DOI matches its Crossref record.

Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

Open access
Kantarjian, Hagop M., O'Brien, Susan, Cortes, Jorge, Giles, Francis J., Faderl, Stefan, Issa, Jean‐Pierre, Garcia‐Manero, Guillermo, Rios, Mary Beth, Shan, Jianqin, Andreeff, Michael, Keating, Michael, Talpaz, Moshe · 2003 · Cancer

Abstract

BACKGROUND: General and site‐specific DNA methylation is associated with tumor progression and resistance in several cancers, including chronic myelogenous leukemia (CML). Decitabine is a hypomethylating agent that has shown encouraging preliminary anti‐CML activity. This study evaluated the activity and toxicity of decitabine in different phases of CML. METHODS: One hundred and thirty patients with CML were treated: 123 with Philadelphia chromosome (Ph)‐positive CML (64 blastic, 51 accelerated, 8 chronic) and 7 with Ph‐negative CML. Decitabine was given at 100 mg/m 2 over 6 hours every 12 hours × 5 days (1000 mg/m 2 per course) in the first 13 patients, 75 mg/m 2 in the subsequent 33 patients, and 50 mg/m 2 in the remaining 84 patients. RESULTS: A total of 552 courses were given to the 130 patients. Only four patients (3%) died during the first course from myelosuppressive complications (three patients) or progressive disease (one patient). Of 64 patients in the CML blastic phase, 18 patients (28%) achieved objective responses. Of these 18 patients, 6 achieved complete hematologic responses (CHR), 2 achieved partial hematologic responses (PHR), 7 achieved hematologic improvements (HI), and 3 returned to the second chronic phase (second CP). Five patients (8%) had cytogenetic responses. Among 51 patients in the accelerated phase, 28 patients (55%) achieved objective responses (12 CHR, 10 PHR, 3 HI, and 3 second CP). Seven patients (14%) had cytogenetic responses. Among eight patients treated in the chronic phase, five (63%) had objective responses. Of seven patients treated for Ph‐negative CML, four (57%) had objective responses. There was no evidence of a dose‐response effect. The estimated 3‐year survival rate was less than 5% in the blastic phase and 27% in the accelerated phase. The only significant toxicity reported was severe myelosuppression, which was delayed, prolonged, and dose dependent. With decitabine 50–75 mg/m 2, the median time to granulocyte recovery above 0.5 × 10 9/L was about 4 weeks. Myelosuppression‐associated complications included febrile episodes in 37% and documented infections in 34%. CONCLUSIONS: Decitabine appears to have significant anti‐CML activity. Future studies should evaluate lower‐dose, longer‐exposure decitabine schedules alone in imatinib‐resistant CML, as well as combinations of decitabine and imatinib in different CML phases. Cancer 2003;98:522–8. © 2003 American Cancer Society. DOI 10.1002/cncr.11543

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.11543

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 227

Metadata

Authors
Kantarjian, H. M., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S., Issa, J., Garcia‐Manero, G., Rios, M. B., Shan, J., Andreeff, M., Keating, M., & Talpaz, M.
Venue
Cancer
Publisher
Wiley
Published
2003-06-13
Volume
98
Issue
3
Pages
522-528
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1987152779
Cited by
227
References
0
FWCI
10.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. https://app.cochat.ai/papers/10.1002/cncr.11543
The paper
Kantarjian, H. M., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S., Issa, J., Garcia‐Manero, G., Rios, M. B., Shan, J., Andreeff, M., Keating, M., & Talpaz, M. (2003). Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. https://doi.org/10.1002/cncr.11543

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.